



# Using Yeast Synthetic Lethality To Inform Drug Combination for Malaria

Suvitha Subramaniam,<sup>a,b</sup> Christoph D. Schmid,<sup>a,b,c</sup> Xue Li Guan,<sup>d</sup> Pascal Mäser<sup>a,b</sup>

<sup>a</sup>Swiss Tropical and Public Health Institute, Basel, Switzerland

<sup>b</sup>University of Basel, Basel, Switzerland

<sup>c</sup>Swiss Institute of Bioinformatics, Basel, Switzerland

<sup>d</sup>Nanyang Technological University, Singapore

**ABSTRACT** Combinatorial chemotherapy is necessary for the treatment of malaria. However, finding a suitable partner drug for a new candidate is challenging. Here we develop an algorithm that identifies all of the gene pairs of *Plasmodium falciparum* that possess orthologues in yeast that have a synthetic lethal interaction but are absent in humans. This suggests new options for drug combinations, particularly for inhibitors of targets such as *P. falciparum* calcineurin, cation ATPase 4, or phosphatidylinositol 4-kinase.

**KEYWORDS** antimalarials, combinatorial chemotherapy, gene orthology, synthetic lethality, yeast genetics

There is a persistent need for new antimalarials due to the evolution of drug-resistant parasites. Under the auspices of the Medicines for Malaria Venture (MMV), new drug candidates that are active against artemisinin-resistant isolates of *Plasmodium falciparum* are being developed; the frontrunners are artefenomel, KAF156, cipargamin, DSM265, MMV390048, ferroquine, and tafenoquine (1, 2). However, the choice of the right partner drug will be critical for the success of these new molecules, as the WHO enforces the application of antimalarials in combination therapy (3). In addition to protecting each other from drug resistance, two molecules to be combined need to be compatible for coformulation, should have matching pharmacokinetic profiles, and must not have unfavorable polypharmacology (4–6). Ideally, the two molecules would potentiate each other, thereby decreasing the duration of treatment and the required doses. Thus, combinatorial chemotherapy not only can reduce the risk of drug resistance but also can enhance drug safety and drug efficacy, enabling the ambitious goal of a “single-exposure radical cure” (7, 8).

Here we propose to support the matchmaking of antimalarial candidates by learning from yeast reverse genetics. *Saccharomyces cerevisiae* is probably the best studied of all eukaryotes. Only about 20% of its protein-coding genes are essential for growth on rich medium (9). High-throughput crossing experiments have shown that many viable *S. cerevisiae* gene deletion mutants possess synthetic phenotypes, i.e., growth defects that become apparent only in the absence of another nonessential gene. The concept of genetic synthetic lethality can be adopted to combination chemotherapy (8, 10–12). The principal idea is to extrapolate from synthetic lethal gene pairs in *S. cerevisiae* to orthologous pairs of genes in *P. falciparum*, assuming that the combined inhibition of the respective gene products will produce a synergistic effect. However, this seemingly straightforward approach is complicated by the fact that *S. cerevisiae* is more closely related to *Homo sapiens* than to *P. falciparum* (13). Thus, a drug combination inferred from yeast synthetic genetic lethality might enhance the toxicity to


Received 26 July 2017 Returned for modification 29 September 2017 Accepted 30 December 2017

Accepted manuscript posted online 22 January 2018

**Citation** Subramaniam S, Schmid CD, Guan XL, Mäser P. 2018. Using yeast synthetic lethality to inform drug combination for malaria. *Antimicrob Agents Chemother* 62:e01533-17. <https://doi.org/10.1128/AAC.01533-17>.

**Copyright** © 2018 Subramaniam et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Pascal Mäser, [pascal.maeser@swisstph.ch](mailto:pascal.maeser@swisstph.ch).



**FIG 1** Graphic representation of the algorithm, with the numbers of *P. falciparum* gene pairs that passed the filters; the final 37 are shown in Table 1. Yellow, *S. cerevisiae*; blue, *P. falciparum*; red, *H. sapiens*.

humans rather than enhancing the antimalarial efficacy. To avoid such a scenario, we developed an algorithm to exclude gene pairs that are conserved in *H. sapiens*.

Yeast synthetic lethal gene pairs were obtained from BioGRID 3.4 (14) and pairs and groups of orthologous genes from the OrthoMCL 5 database, based on the similarity of the derived protein sequences (15, 16). Mining the OrthoMCL database with the 16,217 synthetic lethal gene pairs of *S. cerevisiae* identified in BioGRID, we found that only 1,505 pairs (9.3%) had direct orthologues in *P. falciparum* for both gene products (Fig. 1). From this set, we tested all of the proteins for the presence of an orthologue in the human proteome, again referring to the downloaded OrthoMCL database. This assessment included direct pairwise orthology between the *P. falciparum* or *S. cerevisiae* protein and a *H. sapiens* protein or indirect orthology in which either the malaria protein or its yeast orthologue belonged to an OrthoMCL group that also contained a human protein (Fig. 1). All of the *P. falciparum* gene pairs for which both gene products tested positive for direct or indirect human orthology were eliminated. This process yielded 37 pairs composed of 55 unique *P. falciparum* proteins that fulfilled the conditions that (i) their direct orthologues in *S. cerevisiae* exhibit synthetic lethality and (ii) at least one of the two proteins has neither a direct nor an indirect orthologue in the human proteome. Therefore, we suggest these pairs as targets for combinatorial chemotherapy. The comparative genomics pipeline (Fig. 1) is built with self-developed Python scripts that are available for download at the GitHub repository (<https://github.com/suvi-subra/SynthLeth>).

The final set of 37 pairs was enriched in druggable proteins (Table 1). Of the 55 proteins in the set, 30 either had been validated as drug targets or had a positive “druggability index,” as predicted by TDR Targets (17). Some of the suggested combinations affected the same pathway, e.g., the pyridoxal kinase-like protein and pyridoxine biosynthesis protein involved in vitamin B<sub>6</sub> metabolism or NAD(P)H-dependent glutamate synthase and NADP-specific glutamate dehydrogenase; the latter is selectively inhibited by isophthalic acid (18), while glutamate synthase had been suggested as a target based on comparative genomics (19). Calcineurin subunit B paired with the *P. falciparum* cation/H<sup>+</sup> antiporter (PfCHA), which is sensitive to known inhibitors such as KB-R7943 (20). Hubs of inferred interactions were *P. falciparum* apurinic/aprimidinic endonuclease 1 (PfAPN1) and the *P. falciparum* U5 small nuclear ribonucleoprotein (PfSNU114) of the spliceosome, both of which are involved in the processing of nucleic acids. Two proteins in the target set were of particular pharmacological interest, namely, *P. falciparum* Ca<sup>2+</sup>-ATPase 4 (PfATP4) and *P. falciparum* phosphatidylinositol 4-kinase (PfPI4K). Either protein is targeted by new antimalarial candidates (21–27).

**TABLE 1** Pairs of *P. falciparum* proteins suggested as targets for combinatorial chemotherapy, based on synthetic lethal genetic interactions in *S. cerevisiae*

Gene 1 identification	Gene 1 product <sup>a</sup>	Gene 2 identification	Gene 2 product
PF14_0492	Calcineurin subunit B	PFF0170w	Cation/H <sup>+</sup> antiporter
PFL0590c	Non-SERCA-type Ca <sup>2+</sup> -transporting P-ATPase 4	PFF0170w	Cation/H <sup>+</sup> antiporter
PFE0485w	Phosphatidylinositol 4-kinase	PFF0305c	Ubiquitin-conjugating enzyme E2
PF08_0031	Dicarboxylate/tricarboxylate carrier	mal_mito_2	Cytochrome <i>c</i> oxidase subunit 1
PFF1105c	Chorismate synthase	PF14_0511	Glucose-6-phosphate dehydrogenase
PFL2465c	Thymidylate kinase	PF13_0176	Apurinic/aprimidinic endonuclease
MAL13P1.346	DNA repair endonuclease	PF13_0176	Apurinic/aprimidinic endonuclease
PFB0160w	ERCC1 nucleotide excision repair protein	PF13_0176	Apurinic/aprimidinic endonuclease
PFF0715c	Endonuclease III homologue	PF13_0176	Apurinic/aprimidinic endonuclease
PFD0865c	Cdc2-related protein kinase 1	PFF0165c	Conserved <i>Plasmodium</i> protein, unknown function
PFL1635w	Sentrin-specific protease 1	PF10_0092	Metallopeptidase
PF13_0251	DNA topoisomerase 3	PF10_0092	Metallopeptidase
PFF0775w	Pyridoxal kinase-like protein	PFF1025c	Pyridoxine biosynthesis protein
PF11_0192	Histone acetyltransferase	PFF1180w	Anaphase-promoting complex subunit
PFL2440w	DNA repair protein	MAL7P1.94	Prefoldin subunit 3
PF11_0087	DNA repair protein	PF10_0041	U5 small nuclear ribonucleoprotein
PFB0445c	ATP-dependent RNA helicase	PF10_0041	U5 small nuclear ribonucleoprotein
PFE0925c	ATP-dependent RNA helicase	PF10_0041	U5 small nuclear ribonucleoprotein
PF10_0294	Pre-mRNA-splicing factor ATP-dependent RNA helicase	PF10_0041	U5 small nuclear ribonucleoprotein
PFC1060c	U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated protein 1	PF10_0041	U5 small nuclear ribonucleoprotein
PF13_0096	U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated protein 2	PF10_0041	U5 small nuclear ribonucleoprotein
PFC0365w	Pre-mRNA-processing factor 19	PF10_0041	U5 small nuclear ribonucleoprotein
PFD0685c	Structural maintenance of chromosomes protein 3	PF10_0041	U5 small nuclear ribonucleoprotein
MAL13P1.214	Phosphoethanolamine <i>N</i> -methyltransferase	PFA0455c	Fatty acid elongation protein, GNS1/SUR4 family
MAL13P1.214	Phosphoethanolamine <i>N</i> -methyltransferase	PFL0950c	Aminophospholipid-transporting P-ATPase
MAL8P1.17	Protein disulfide isomerase	PF10_0092	Metallopeptidase
MAL8P1.17	Protein disulfide isomerase	PFB0920w	DnaJ protein
PF07_0029	Heat shock protein 86	MAL13P1.139	Mitochondrial fission 1 protein
PF07_0029	Heat shock protein 86	PF10300w	Vacuolar protein sorting-associated protein 46
PF14_0068	rRNA 2'- <i>O</i> -methyltransferase fibrillar	PFF1180w	Anaphase-promoting complex subunit
PF14_0261	Proliferation-associated protein 2g4	PF14_0612	Zinc finger protein
PF14_0286	NADP-specific glutamate dehydrogenase	PF14_0334	NAD(P)H-dependent glutamate synthase
PF14_0401	tRNA import protein	PF13_0257	Glutamate-tRNA ligase
PFC0510w	E3 ubiquitin-protein ligase	PF10300w	Vacuolar protein sorting-associated protein 46
PFE0750c	Pre-mRNA-splicing factor	PF14_0688	Pre-mRNA-splicing factor ISY1
PFF1385c	Conserved <i>Plasmodium</i> protein	PFB0920w	DnaJ protein
PFL1140w	Vacuolar iron transporter	PFL0725w	Thioredoxin peroxidase 2

<sup>a</sup>SERCA, sarcoplasmic reticulum calcium transport ATPase; ERCC1, excision repair cross-complementation group 1.

PfATP4 is the target of cipargamin and paired with PfCHA (Table 1), suggesting testing for potential synergy between cipargamin and KB-R7943. PfPI4K, the target of imidazolopiperazines and MMV390048, paired with ubiquitin-conjugating enzyme E2 (Table 1). An inhibitor of Atg8-Atg3 interactions was identified from the MMV Malaria Box (28), and ubiquitin-protein ligase E3 was proposed as an antimalarial target (29). The inferred link between phosphatidylinositol 4-kinase and ubiquitination suggests testing for potential synergy between PfPI4K inhibitors and *P. falciparum* proteasome inhibitors (30–32).

The present approach critically depends on the existence of *S. cerevisiae* genes that (i) possess synthetic lethal phenotypes and (ii) are orthologous to known *P. falciparum* drug target genes. This seems contradictory; by definition, drug targets are essential and genes with synthetic phenotypes are nonessential. However, we show here that several validated drug targets of *P. falciparum* possess orthologues in *S. cerevisiae* that are nonessential (Table 1). Phosphoethanolamine methyltransferase and phosphatidylinositol 4-kinase (Table 1), for instance, have been demonstrated to be essential enzymes in *P. falciparum* (24, 33). Most of the genes that are conserved between *S. cerevisiae* and *P. falciparum* also have an orthologue in *H. sapiens* (the OrthoMCL database contains only 80 yeast genes with an orthologue in *P. falciparum* but not in

*H. sapiens*). We speculate that, of the conserved genes that are essential in yeast, many may also be essential in *H. sapiens* and their products not suitable as drug targets. On the other hand, conserved genes that are devoid of synthetic phenotypes in yeast might also be dispensable in *P. falciparum* and thus not suitable either. The conserved genes that have synthetic lethal phenotypes in yeast might be the most interesting pharmacologically.

The proposed algorithm strongly narrows the target space for antimalarial drug combinations by including potentially synergistic interactions involving efficacy against *P. falciparum* as well as toxicity against *H. sapiens*. The fact that it relies on genome-scale experimental data from *S. cerevisiae* rather than *P. falciparum* makes the algorithm straightforward and unbiased but also difficult to validate experimentally. Presently, experimental testing of the identified target pairs in Table 1 is precluded by the lack of inhibitors for most of the proposed targets. However, we think that the presence of targets such as PfPI4K and PfATP4 in Table 1 validates the algorithm, and we hope that the algorithm will help identify future combinations of antimalarial molecules that potentiate each other.

## ACKNOWLEDGMENTS

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

We are grateful to Andrew M. Waterhouse for help with Python programming and to Matthias Rottmann for critical reading of the manuscript.

## REFERENCES

- Medicines for Malaria Venture. 2017. MMV drug development portfolio. <https://www.mmv.org/research-development/mmv-supported-projects>.
- White NJ. 2016. Can new treatment developments combat resistance in malaria? *Expert Opin Pharmacother* 17:1303–1307. <https://doi.org/10.1080/14656566.2016.1187134>.
- World Health Organization. 2010. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
- Wells TN, Hoof van Huijsdijnen R, Van Voorhis WC. 2015. Malaria medicines: a glass half full? *Nat Rev Drug Discov* 14:424–442. <https://doi.org/10.1038/nrd4573>.
- Kremsner PG, Krishna S. 2004. Antimalarial combinations. *Lancet* 364:285–294. [https://doi.org/10.1016/S0140-6736\(04\)16680-4](https://doi.org/10.1016/S0140-6736(04)16680-4).
- malERA Consultative Group on Drugs. 2011. A research agenda for malaria eradication: drugs. *PLoS Med* 8:e1000402. <https://doi.org/10.1371/journal.pmed.1000402>.
- Diagana TT. 2015. Supporting malaria elimination with 21st century antimalarial agent drug discovery. *Drug Discov Today* 20:1265–1270. <https://doi.org/10.1016/j.drudis.2015.06.009>.
- Conde-Pueyo N, Munteanu A, Sole RV, Rodriguez-Caso C. 2009. Human synthetic lethal inference as potential anti-cancer target gene detection. *BMC Syst Biol* 3:116. <https://doi.org/10.1186/1752-0509-3-116>.
- Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau-Danila A, Anderson K, Andre B, Arkin AP, Astromoff A, El-Bakkoury M, Bangham R, Benito R, Brachat S, Campanaro S, Curtiss M, Davis K, Deutschbauer A, Entian KD, Flaherty P, Foury F, Garfinkel DJ, Gerstein M, Gotte D, Guldener U, Hegemann JH, Hempel S, Herman Z, Jaramillo DF, Kelly DE, Kelly SL, Kotter P, LaBonte D, Lamb DC, Lan N, Liang H, Liao H, Liu L, Luo C, Lussier M, Mao R, Menard P, Ooi SL, Revuelta JL, Roberts CJ, Rose M, Ross-Macdonald P, Scherens B, Schimmack G, Shafer B, Shoemaker DD, Sookhai-Mahadeo S, Storms RK, Strathern JN, Valle G, Voet M, Volckaert G, Wang C, Ward TR, Wilhelmy J, Winzeler EA, Yang Y, Yen G, Youngman E, Yu K, Bussey H, Boeke JD, Snyder M, Philippsen P, Davis RW, Johnston M. 2002. Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature* 418:387–391. <https://doi.org/10.1038/nature00935>.
- Fügi MA, Kaiser M, Tanner M, Schneiter R, Mäser P, Guan XL. 2015. Match-making for posaconazole through systems thinking. *Trends Parasitol* 31:46–51. <https://doi.org/10.1016/j.pt.2014.11.004>.
- Kaelin WG, Jr. 2005. The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer* 5:689–698. <https://doi.org/10.1038/nrc1691>.
- Roemer T, Boone C. 2013. Systems-level antimicrobial drug and drug synergy discovery. *Nat Chem Biol* 9:222–231. <https://doi.org/10.1038/nchembio.1205>.
- Adl SM, Simpson AG, Farmer MA, Andersen RA, Anderson OR, Barta JR, Bowser SS, Brugerolle G, Fensome RA, Fredericq S, James TY, Karpov S, Kugrens P, Krug J, Lane CE, Lewis LA, Lodge J, Lynn DH, Mann DG, McCourt RM, Mendoza L, Moestrup O, Mozley-Standridge SE, Nerad TA, Shearer CA, Smirnov AV, Spiegel FW, Taylor MF. 2005. The new higher level classification of eukaryotes with emphasis on the taxonomy of protists. *J Eukaryot Microbiol* 52:399–451. <https://doi.org/10.1111/j.1550-7408.2005.00053.x>.
- Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. 2006. BioGRID: a general repository for interaction datasets. *Nucleic Acids Res* 34:D535–D539. <https://doi.org/10.1093/nar/gkj109>.
- Chen F, Mackey AJ, Stoeckert CJ, Jr, Roos DS. 2006. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups. *Nucleic Acids Res* 34:D363–D368. <https://doi.org/10.1093/nar/gkj123>.
- Fischer S, Brunk BP, Chen F, Gao X, Harb OS, Iodice JB, Shanmugam D, Roos DS, Stoeckert CJ, Jr. 2011. Using OrthoMCL to assign proteins to OrthoMCL-DB groups or to cluster proteomes into new ortholog groups. *Curr Protoc Bioinformatics Chapter 6:Unit 6.12.1–6.12.19*.
- Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ, Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, Nwaka S, Overington JP, Pain A, Paolini GV, Pieper U, Ralph SA, Riechers A, Roos DS, Sali A, Shanmugam D, Suzuki T, Van Voorhis WC, Verlinde CL. 2008. Genomic-scale prioritization of drug targets: the TDR Targets database. *Nat Rev Drug Discov* 7:900–907. <https://doi.org/10.1038/nrd2684>.
- Aparicio IM, Marin-Menendez A, Bell A, Engel PC. 2010. Susceptibility of *Plasmodium falciparum* to glutamate dehydrogenase inhibitors: a possible new antimalarial target. *Mol Biochem Parasitol* 172:152–155. <https://doi.org/10.1016/j.molbiopara.2010.04.002>.
- Ludin P, Woodcroft B, Ralph SA, Maser P. 2012. In silico prediction of antimalarial drug target candidates. *Int J Parasitol Drugs Drug Resist* 2:191–199. <https://doi.org/10.1016/j.ijpddr.2012.07.002>.
- Salcedo-Sora JE, Ward SA, Biagini GA. 2012. A yeast expression system for functional and pharmacological studies of the malaria parasite Ca<sup>2+</sup>/H<sup>+</sup> antiporter. *Malar J* 11:254. <https://doi.org/10.1186/1475-2875-11-254>.
- Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, Gonzalez-Paez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP,

- Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagona TT. 2010. Spiroindolones, a potent compound class for the treatment of malaria. *Science* 329:1175–1180. <https://doi.org/10.1126/science.1193225>.
22. Goldgof GM, Durrant JD, Otilie S, Vigil E, Allen KE, Gunawan F, Kostylev M, Henderson KA, Yang J, Schenken J, LaMonte GM, Manary MJ, Murao A, Nachon M, Stanhope R, Prescott M, McNamara CW, Slayman CW, Amaro RE, Suzuki Y, Winzeler EA. 2016. Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (cipargamin) is a P-type ATPase inhibitor. *Sci Rep* 6:27806. <https://doi.org/10.1038/srep27806>.
  23. Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackelford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. 2014. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of *Plasmodium*. *Proc Natl Acad Sci U S A* 111:E5455–E5462. <https://doi.org/10.1073/pnas.1414221111>.
  24. McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman AM, Decherer KJ, Kumar TS, Henrich PP, Gagaring K, Ibanez M, Kato N, Kuhen KL, Fischli C, Nagle A, Rottmann M, Plouffe DM, Bursulaya B, Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken CH, Glynn RJ, Bodenreider C, Fidock DA, Diagona TT, Winzeler EA. 2013. Targeting *Plasmodium* PI(4)K to eliminate malaria. *Nature* 504:248–253. <https://doi.org/10.1038/nature12782>.
  25. Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagona TT, Kirk K. 2013. Na<sup>+</sup> regulation in the malaria parasite *Plasmodium falciparum* involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. *Cell Host Microbe* 13:227–237. <https://doi.org/10.1016/j.chom.2012.12.006>.
  26. Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C, Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagona TT, Bifani P. 2017. The *Plasmodium* PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated *Plasmodium falciparum* ring-stage parasites. *Sci Rep* 7:2325. <https://doi.org/10.1038/s41598-017-02440-6>.
  27. Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ, Bantscheff M, Ruecker A, Blagborough AM, Zakutansky SE, Zeeman AM, White KL, Shackelford DM, Mannila J, Morizzi J, Scheurer C, Angulo-Barturen I, Martinez MS, Ferrer S, Sanz LM, Gamo FJ, Reader J, Botha M, Decherer KJ, Sauerwein RW, Tungtaeng A, Vanachayangkul P, Lim CS, Burrows J, Witty MJ, Marsh KC, Bodenreider C, Rochford R, Solapure SM, Jimenez-Diaz MB, Wittlin S, Charman SA, Donini C, Campo B, Birkholtz LM, Hanson KK, Drewes G, Kocken CHM, Delves MJ, Leroy D, Fidock DA, Waterson D, Street LJ, Chibale K. 2017. Antimalarial efficacy of MMV390048, an inhibitor of *Plasmodium* phosphatidylinositol 4-kinase. *Sci Transl Med* 9:eaad9735. <https://doi.org/10.1126/scitranslmed.aad9735>.
  28. Hain AU, Bartee D, Sanders NG, Miller AS, Sullivan DJ, Levitskaya J, Meyers CF, Bosch J. 2014. Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the Medicines for Malaria Venture Malaria Box active in blood and liver stage *Plasmodium falciparum* parasites. *J Med Chem* 57:4521–4531. <https://doi.org/10.1021/jm401675a>.
  29. Jain J, Jain SK, Walker LA, Tekwani BL. 2017. Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads. *BMC Pharmacol Toxicol* 18:40. <https://doi.org/10.1186/s40360-017-0147-4>.
  30. LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J, Antonova-Koch Y, Orjuela-Sanchez P, Boyle CA, Vigil E, Wang L, Goldgof GM, Gerwick L, O'Donoghue AJ, Winzeler EA, Gerwick WH, Otilie S. 2017. Development of a potent inhibitor of the *Plasmodium* proteasome with reduced mammalian toxicity. *J Med Chem* 60:6721–6732. <https://doi.org/10.1021/acs.jmedchem.7b00671>.
  31. Li H, O'Donoghue AJ, van der Linden WA, Xie SC, Yoo E, Foe IT, Tilley L, Craik CS, da Fonseca PC, Bogoy M. 2016. Structure- and function-based design of *Plasmodium*-selective proteasome inhibitors. *Nature* 530:233–236. <https://doi.org/10.1038/nature16936>.
  32. Tschan S, Brouwer AJ, Werkhoven PR, Jonker AM, Wagner L, Knittel S, Aminake MN, Pradel G, Joanny F, Liskamp RM, Mordmuller B. 2013. Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors. *Antimicrob Agents Chemother* 57:3576–3584. <https://doi.org/10.1128/AAC.00742-12>.
  33. Bobenchik AM, Witola WH, Augagneur Y, Nic Lochlainn L, Garg A, Pachikara N, Choi JY, Zhao YO, Usmani-Brown S, Lee A, Adjalley SH, Samanta S, Fidock DA, Voelker DR, Fikrig E, Ben Mamoun C. 2013. *Plasmodium falciparum* phosphoethanolamine methyltransferase is essential for malaria transmission. *Proc Natl Acad Sci U S A* 110:18262–18267. <https://doi.org/10.1073/pnas.1313965110>.